{"id":637063,"date":"2023-02-06T19:44:01","date_gmt":"2023-02-06T19:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=637063"},"modified":"2023-02-06T19:44:01","modified_gmt":"2023-02-06T19:44:01","slug":"food-allergy-clinical-trials-emerging-drugs-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/food-allergy-clinical-trials-emerging-drugs-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight_637063.html","title":{"rendered":"Food Allergy Clinical Trials, Emerging Drugs, Key Companies | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1675680107.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Food Allergy Clinical Trials, Emerging Drugs, Key Companies | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1675680107.jpeg\" alt=\"Food Allergy Clinical Trials, Emerging Drugs, Key Companies | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cFood Allergy- Pipeline Insight, 2023\u201d report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&#8216;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/food-allergy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Food Allergy Pipeline Insight 2023<\/a>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Food Allergy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Food Allergy pipeline domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/food-allergy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Food Allergy Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over <strong>35+<\/strong> Food Allergy pipeline therapies are in various stages of development, and their anticipated acceptance in the Food Allergy market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Food Allergy companies developing novel drug candidates to improve the Food Allergy treatment landscape include <strong>DBV technologies, Genentech, Regeneron Pharmaceuticals, Alladapt Immunotherapeutics<\/strong>, and others.<\/li>\n<li>Promising Food Allergy pipeline therapies in various stages of development include <strong>Viaskin Peanut, Omalizumab, Dupilumab, ADP101<\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Food Allergy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">A food allergy occurs when the body&rsquo;s immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens. The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The negative predictive accuracy of a skin prick test weal of &lt; 3mm greater than the negative control is high, usually &gt; 95%, and is strong evidence that the food may be consumed without severe, immediate food-allergic reactions. A positive SPT, even a weal of 3 mm or more, may be clinically irrelevant, as the patient may tolerate the ingested food. SPTs may also remain positive after the development of tolerance to the specific food. The foods to which an individual is allergic should be avoided, as therapeutic intervention (tertiary prevention) in patients with food allergy.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">It must strike a precautionary equilibrium between the demands of prohibitive measures against allergy care and quality of life. Hypersensitivity reactions are often treated with medications. . Epinephrine is the only medication that is effective for the treatment of anaphylaxis. Additional medicatioons include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/food-allergy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">food allergy treatment algorithm and diagnosis<\/a>.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Food Allergy Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\">Viaskin Peanut: DBV technologies<\/p>\n<p style=\"text-align: justify;\">Investigational Viaskin&reg; Peanut therapeutic treatment is based on epicutaneous immunotherapy, or EPIT&trade;. &nbsp; This potential new class of immunotherapey is designed to work by delivering allergens to the immune system through intact skin using our proprietary Viaskin&reg; technology. For those patients facing potentially life-threatening food allergies, this potential immunotherapy treatment aims to desensitize them to allergens by delivering compounds in small quantities into the outer layers of the skin. The investigational EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about the emerging Food Allergy drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/food-allergy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Food Allergy Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Food Allergy Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DBV technologies<\/li>\n<li>Genentech<\/li>\n<li>Regeneron Pharmaceuticals<\/li>\n<li>Alladapt Immunotherapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Food Allergy Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Viaskin Peanut<\/li>\n<li>Omalizumab<\/li>\n<li>Dupilumab<\/li>\n<li>ADP101<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Food Allergy Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>By development stage<\/li>\n<li>By product type<\/li>\n<li>By route of administration<\/li>\n<li>By molecule type<\/li>\n<li>By MOA type&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Food Allergy Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage:&nbsp;Global&nbsp;<\/strong><\/li>\n<li><strong>Key Food Allergy Companies:<\/strong> DBV technologies, Genentech, Regeneron Pharmaceuticals, Alladapt Immunotherapeutics, and others<\/li>\n<li><strong>Key Food Allergy Pipeline Therapies:<\/strong> Viaskin Peanut, Omalizumab, Dupilumab, ADP101, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about the Food Allergy treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/food-allergy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Food Allergy Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Other Trending Reports:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Asthma Diagnostic Devices Market<\/li>\n<li>Chronic Obstructive Pulmonary Disease Treatment Devices Market<\/li>\n<li>Airway Management Devices Market<\/li>\n<li>Cough Assist Devices Market<\/li>\n<li>Pulse Oximeters Market<\/li>\n<li>Hemodialysis Catheter Devices Market<\/li>\n<li>Chronic Spontaneous Urticaria Market&nbsp;<\/li>\n<li>Gender Dysphoria Market<\/li>\n<li>Germany Healthcare Outlook<\/li>\n<li>Biopsy Devices Pipeline Insight<\/li>\n<li>Bacterial Conjunctivitis Market<\/li>\n<li>Infliximab Biosimilar Insight<\/li>\n<li>Eosinophilic Asthma Market<\/li>\n<li>Cushing Syndrome Market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Contact Us<\/strong><\/p>\n<p style=\"text-align: justify;\">Kritika Rehani<\/p>\n<p style=\"text-align: justify;\">info@delveinsight.com&nbsp;<\/p>\n<p style=\"text-align: justify;\">+1(919)321-6187&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=food-allergy-clinical-trials-emerging-drugs-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=food-allergy-clinical-trials-emerging-drugs-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s, \u201cFood Allergy- Pipeline Insight, 2023\u201d report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/food-allergy-clinical-trials-emerging-drugs-key-companies-a-drug-pipeline-analysis-report-2023-delveinsight_637063.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-637063","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/637063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=637063"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/637063\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=637063"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=637063"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=637063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}